Artificial Ligaments | Market Size, Share & Growth Report 2025-2033
The Artificial Ligaments Market Report is Segmented by Product Type (Polyester Ligaments, Silk Ligaments, Carbon Ligaments, Ceramic Ligaments, and Others), Application (Orthopedic Surgeries, Sports Injuries, Trauma Cases, Joint Reconstruction, and Others), Distribution Channel (Hospitals, Orthopedic Clinics, Ambulatory Surgical Centers, Online Stores, and Others), Material Type (Polyethylene, Dacron, Polypropylene, PTFE, and Others).
Artificial Ligaments Market
Market Analysis
How the market stands today, and what is shaping it
The global artificial ligaments market was estimated at approximately USD 41.5 million in 2025 and is projected to reach around USD 87.67 million by 2033, representing a CAGR of approximately 9.80% during 2025–2033, based on Core Market Research estimates. The market supplies woven synthetic ligament implants, predominantly polyester, for knee and joint reconstruction, sports injury and trauma surgery, purchased through hospitals and ambulatory surgical centres. Growth is supported by knee injuries accounting for over 42.5% of the market in 2023, by implants that avoid harvesting tendon from the patient, by established use in Canada and European countries, and by revision cases where available autograft has been exhausted. Expansion is constrained by allografts being largely preferred by surgeons, by autograft costing nothing beyond surgical time, and by the United States FDA not having approved the category's principal product. Published sizing places artificial tendons and ligaments at about USD 32.4 million for 2023, and Europe leads on documented commercial concentration.
Market Dynamics
Key market dynamics and their impact on the industry landscape
Market Drivers
- Knee injuries accounted for over 42.5% of this market in 2023, and anterior cruciate ligament rupture is common in organised sport, so the underlying procedure volume is substantial and rising with sports participation.
- Woven polyester implants allow reconstruction without harvesting tendon from the patient, which removes donor site morbidity and the additional surgical dissection that taking an autograft requires from the same operation.
- The LARS implant is established in Canada and across European countries, so regulatory acceptance in multiple developed markets supports continued use even where the United States has not approved it.
- Ligament reconstruction is planned elective surgery billed within a procedure, so the implant is purchased against a scheduled operating list rather than requiring a separate coverage decision for the device.
- Revision cases and multi-ligament injuries can exhaust the patient's available autograft tissue, which leaves a synthetic implant as one of the few remaining options and creates demand independent of first-line preference.
Market Challenges
- The stored figures of USD 1.2 billion for 2024 were roughly thirty times the published sizing for this category, which places artificial tendons and ligaments at about USD 32.4 million for 2023 growing toward USD 96.4 million by 2033.
- The product competes against the patient's own tissue. Allografts are largely preferred by surgeons for faster recovery without additional damage to the patient, and autograft costs nothing to acquire beyond surgical time.
- The United States FDA has not approved the LARS artificial ligament, so the largest orthopaedic market in the world is substantially closed to the category's principal product while Canada and European countries use it.
- Four of the five supplied product types describe materials that were investigated rather than bought. Carbon ligaments did not survive clinical experience, ceramic is not a recognised ligament material, and silk remains a research scaffold.
- Material Type duplicates Product Type rather than cutting across it, since Dacron is a trade name for polyester, so the two segmentations describe the same implants twice under different headings.
Opportunities
- Bioinductive and augmentation implants are reaching markets that permanent synthetic replacements did not, with Smith+Nephew able to market REGENETEN for extra-articular ligament injuries in the United States from 2025.
- Resorbable scaffolds that host tissue ingrowth rather than remaining permanently could address the durability concerns that limited earlier synthetics, and silk is among the materials being studied for that purpose.
- Markets with less developed allograft tissue banking may adopt synthetic implants more readily, since the alternative that competes most directly with them is simply less available there.
- Revision and multi-ligament reconstruction, where available autograft has been exhausted, is a defensible clinical niche that does not require displacing first-line preference for the patient's own tissue.
- A United States regulatory pathway for an established synthetic ligament would open by far the largest orthopaedic market to products already in routine use across Canada and Europe.
Trends and Insights
Key market trends shaping the industry landscape
Competing Against Free Tissue
High impactLong-termAllografts are largely preferred by surgeons for faster recovery without additional damage to the patient's own tissue.
Insight: A device competing against the patient's own tendon faces a rival with no acquisition cost and no implant, which caps this market's size regardless of how good the synthetic becomes.
Closed Out of the Largest Market
High impactLong-termThe LARS artificial ligament is widely used in Canada and European countries while the United States FDA has not approved it.
Insight: A category can be routine practice in several developed health systems and commercially absent from the biggest one, which means regulatory status rather than clinical evidence sets this market's ceiling.
A Market of Tens of Millions
High impactShort-termPublished sizing placed artificial tendons and ligaments at about USD 32.4 million in 2023, with an incremental 2020 to 2024 forecast of roughly USD 15.5 million.
Insight: Figures in the billions circulating for this category almost certainly describe ligament repair devices and fixation hardware generally, not the synthetic implants the name refers to.
Specialists, Not Orthopaedic Majors
Medium impactLong-termThe recognised manufacturers are European specialists and a Chinese supplier rather than the large orthopaedic groups.
Insight: Where a category is small and clinically contested, the majors participate through adjacent products instead, which leaves the field to firms whose whole business depends on it.
Augmentation Replacing Replacement
Medium impactMid-termBioinductive implants for extra-articular ligament injuries became marketable in the United States in 2025, while permanent synthetic replacements did not.
Insight: The commercially viable direction is helping native tissue heal rather than substituting for it, which is a different product concept from the one this market is named after.
Segment Analysis
Market segmentation by product type, application, distribution channel, material type
Polyester Ligaments are effectively the whole of this market in commercial terms, since the established synthetic implants are woven polyethylene terephthalate. The other named categories describe the field's history more than its present. Carbon Ligaments were investigated seriously in the 1980s and did not survive clinical experience. Ceramic Ligaments are not a recognised implant class, since ceramic is stiff and brittle and a ligament must stretch and recover. Silk Ligaments remain a research material, studied as a resorbable scaffold that tissue grows into rather than a permanent replacement, and no silk ligament has an established commercial position. Readers should treat four of these five values as describing what has been tried rather than what is bought.
Geography Analysis
Regional market analysis
North America
North America is the anomaly in this market: the largest orthopaedic market in the world, and largely closed to its principal product. The LARS artificial ligament is widely used in Canada while the United States FDA has not approved it, which splits the region in two along a regulatory line rather than a clinical one. United States practice relies on autograft and allograft for anterior cruciate ligament reconstruction, supported by a well-developed tissue banking infrastructure that reduces the case for a synthetic alternative. What is reaching the United States market is augmentation and bioinductive implants rather than permanent synthetic replacements, with Smith+Nephew able to market its REGENETEN Bioinductive Implant for extra-articular ligament injuries there from 2025.
Europe
Europe is the largest market here on documented commercial concentration rather than on a measured regional market size, and the concentration is unusually plain: the recognised specialists are European. Movmedix in France manufactures the LARS implant and describes itself as the world leader in this field, Cousin Biotech and Orthomed are also French, and Xiros Ltd. supplies Neoligaments products from the United Kingdom. Clinical practice in several European countries has remained more willing to use synthetic ligaments than practice in the United States. No regional market size, revenue or growth figure was identified for any region in this market, and no company examined reports artificial ligament revenue separately, so both regional rankings here are documented judgements rather than measurements.
Asia Pacific
No market size, revenue or growth figure specific to Asia Pacific was identified for this market. The region matters on the supply side as well as the demand side, with Shanghai PINE&POWER Biotech among the named manufacturers, which is notable in a category otherwise dominated by European specialists. Clinical adoption of synthetic ligaments has been more willing in parts of the region than in the United States, and allograft tissue banking infrastructure is less developed in several markets, which removes the alternative that competes most directly with a synthetic implant. Rising participation in organised sport increases the underlying procedure volume.
Latin America
No market size, revenue or access figure specific to Latin America was identified for this market. Ligament reconstruction is concentrated in private hospitals and sports medicine centres, where the patient population able to fund elective knee surgery is concentrated. Autograft is the default where implant cost is a constraint, since taking the patient's own tissue adds surgical time rather than device expense. Synthetic implants are imported rather than manufactured regionally, which adds cost to an option already competing against a free graft.
Middle East & Africa
No market size, revenue or access figure specific to the Middle East and Africa was identified for this market. Gulf states operate sports medicine and orthopaedic centres that purchase current implants directly, and participation in organised sport there supports a genuine if small procedure volume. Across much of Africa, elective ligament reconstruction is not widely available, and where it is performed autograft is used because it requires no implant purchase. The region contributes very little to this market's value.
Competitive Landscape
Key players and market positioning analysis
This market is supplied by specialists rather than by the large orthopaedic groups, which is itself the clearest statement of its size and standing. Movmedix, formerly LARS and manufacturing orthopaedic and trauma implants for 30 years, holds the strongest position, describing itself as the world leader in the development and manufacture of artificial ligaments. Its implant is established in Canada and across European countries, though the United States FDA has not approved it. Xiros Ltd. competes from the United Kingdom through its Neoligaments range, built on woven polyester constructs for ligament reconstruction and repair. Cousin Biotech and Orthomed S.A.S. are both French, which alongside Movmedix makes this an unusually French market at the manufacturing level. Shanghai PINE&POWER Biotech supplies from China and is the principal named participant outside Europe. Corin Group distributes LARS ligament repair and reconstruction solutions without manufacturing them. Smith+Nephew, Zimmer Biomet and Arthrex participate in ligament pathology through fixation, augmentation and bioinductive products rather than synthetic replacements, which is why they are absent from the Major Players list here. The factors that decide outcomes are regulatory clearance in each territory, long-term clinical follow-up data against autograft and allograft comparators, and surgeon familiarity in the small number of centres that use these implants routinely.
Major Players
Leading companies in the market
Industry Developments
5 recorded developments
Smith+Nephew became able to market its REGENETEN Bioinductive Implant for extra-articular ligament injuries in the United States. Bioinductive and augmentation approaches are reaching the market where permanent synthetic replacements historically did not.
Movmedix, formerly LARS and manufacturing orthopaedic and trauma implants for 30 years, described itself as the world leader in the development and manufacture of artificial ligaments. Leadership in this market rests with specialists rather than large orthopaedic groups.
The LARS artificial ligament remained widely used in Canada and across European countries while the United States FDA had not approved it. A synthetic implant established in several developed markets but absent from the largest one is unusual in orthopaedics.
Published sizing placed artificial tendons and ligaments at about USD 32.4 million for 2023, projected toward roughly USD 96.4 million by 2033 at 11.5%. Knee injuries accounted for over 42.5% of the market that year.
Technavio forecast the global artificial ligaments and tendons market to grow by about USD 15.5 million across 2020 to 2024, naming Artelon and Cousin Biotech among the participants. An incremental forecast of that size confirms a market measured in tens of millions.
Table of Contents
13 comprehensive chapters
1.1 Market Definition
1.2 Scope of the Study
1.3 Research Objectives
2.1 Research Approach
2.2 Data Sources
2.3 Market Estimation Approach
2.4 Forecast Assumptions
2.5 Research Limitations
3.1 Market Overview
3.2 Market Size and Forecast
3.3 Key Findings
3.4 Market Structure
4.1 Market Drivers
4.2 Market Challenges
4.3 Market Opportunities
4.4 Market Trends and Insights
5.1 Market Segmentation Overview
5.2 By Product Type
5.3 By Application
5.4 By Distribution Channel
5.5 By Material Type
6.1 North America
6.2 Europe
6.3 Asia Pacific
6.4 Latin America
6.5 Middle East & Africa
6.6 Regional Market Comparison
7.1 Industry Developments
7.2 Industry Timeline
8.1 Market Structure and Competitive Positioning
8.2 Major Players
8.3 Strategic Developments
8.4 Key Competitive Factors
9.1 Movmedix
9.2 Xiros Ltd.
9.3 Cousin Biotech
9.4 Orthomed S.A.S.
9.5 Shanghai PINE&POWER Biotech
10.1 Market Size and Growth Outlook
10.2 Regional Market Outlook
10.3 Future Market Trends
10.4 Key Risks to the Forecast
11.1 Growth Opportunities
11.2 Key Risks and Constraints
11.3 Strategic Considerations
13.1 Glossary of Terms
13.2 Abbreviations
13.3 Research References
Scope of the Report
Report coverage and methodology
Study Period
Base Year: 2025
Forecast Period: 2025 - 2033
Geographic Scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Covered
Movmedix, Xiros Ltd., Cousin Biotech, Orthomed S.A.S. + more
Data Sources
Primary research, industry interviews, regulatory filings, company reports
Frequently Asked Questions
Common questions about this report
Ready to Get the Full Report?
Access comprehensive market insights, detailed analysis, and strategic recommendations to make informed business decisions.